Nicox launches new website for businesses and investors


Sophia Antipolis Cédex, FRANCE

Press release
Nicox launches new website for businesses and investors

October 4, 2021 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announces the launch of its new corporate and investor website.

The company’s new website,, features:

  • New visual image for Nicox
  • Company presentation video
  • Video on the mechanism of action of NCX 470, our lead product candidate in glaucoma
  • New layout and easier access to key Company information

Nicox is an international ophthalmology company with two product candidates in clinical development – one in phase 3 in glaucoma and another in phase 2b in blepharitis – and recurring license revenues from partners on two commercialized products.

About Nicox
Nicox SA is an international ophthalmology company that develops innovative solutions to help maintain vision and improve eye health. Nicox’s primary clinical development program is NCX 470, a novel nitric oxide donor prostaglandin analogue for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates income from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb and ZERVIATE® in allergic conjunctivitis, licensed in several geographies, including Eyevance Pharmaceuticals, LLC, in the United States and Ocumension Therapeutics in China and the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information about Nicox, its products or its pipeline, please visit:

Analyst coverage

Bryan, Garnier & Co Victor Floc’h Paris, France
Cantor Fitzgerald Louise Chen New York, United States
Edison Investment Research Pooya Hemami London, United Kingdom
HC Wainwright & Co Yi Chen New York, United States
Kepler Cheuvreux Damien Choplain Paris, France

The opinions expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. In addition, the information in their reports may not be correct or up to date. Nicox disclaims any obligation to correct or update information contained in analyst reports.
Gavin Spencer
Executive Vice-President, Chief Business Officer
& Head of business development
T +33 (0) 4 97 24 53 00
[email protected]
Investors and media
United States and Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
[email protected]
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0) 6 27 74 74 49
[email protected]
Forward-looking statements
The information contained in this document is subject to change without notice. This information includes forward-looking statements. These forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of Nicox SA management and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisers or agents, do not undertake and have no obligation to provide updates or revise forward-looking statements.

The risk factors likely to have a significant effect on Nicox’s activity are presented in the 3rd chapter of the ‘Universal registration document, annual financial report and management report 2020‘deposited with the French Financial Markets Authority (AMF) as of March 1, 2021 available on the Nicox website (

Nicox SA
Drakkar 2
Building D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0) 4 97 24 53 00
F +33 (0) 4 97 24 53 99
  • FR_Website launch_20211004_F


FR_Website launch_20211004_F


Previous How to increase your online visibility and attract more customers
Next Food Extrusion Market Worth $ 99.7 Billion By 2026

No Comment

Leave a reply

Your email address will not be published.